(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
1. A compound that is:
or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
2. A pharmaceutical composition comprising the corn pound or isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof of claim 1 ; and one or more pharmaceutically acceptable excipients.
3. A method for inhibiting PI3K enzymatic activity, comprising contacting a PI3K enzyme with the compound or isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof of claim 1 .
4. A method for the treatment or amelioration of one or more symptoms of a PI3K-mediated disorder, disease, or condition in a subject, comprising administering to the subject the compound or isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof of claim 1 .
5. The method of claim 4 , wherein the PI3K-mediated disorder, disease, or condition is a cancer.
6. The method of claim 5 , wherein the cancer is a hematological cancer.
7. The method of claim 6 , wherein the hematological cancer is chronic lymphocytic leukemia or non-Hodgkin's lymphoma.